News for AstraZeneca PLC (ZEG.DE)

OpenAI, a leader in the artificial intelligence sector, is projecting significant revenue growth over the next decade. According to internal documents, the comp

TempusAI (TEM) has seen a rise in its stock following the announcement of a significant $200 million expansion in its strategic partnership with AstraZeneca (AZ

TempusAI (TEM) has embarked on long-term collaborations with AstraZeneca (AZN) and Pathos AI, Inc., focusing on the creation of a comprehensive multimodal found

AstraZeneca (AZN), in collaboration with Daiichi Sankyo, has announced promising interim results from the phase 3 DESTINY-Breast09 trial involving Enhertu. In t

Focus on oncology, cardiovascular, and respiratory therapeutic areas.Strong pipeline with multiple late-stage clinical trials.Risks include regulatory challeng

We recently published a list of 10 Best UK Stocks to Buy According to Billionaires. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against other best UK stocks to invest in. Like most of the world, the United Kingdom is also facing slower economic growth in 2025, […]

Shares of AstraZeneca PLC (AZN) fell 4.47% in mid-day trading on Apr 9. The stock reached an intraday low of $61.24, before recovering slightly to $62.00, d

AstraZeneca's (AZN) shares decline 4.9% amid looming U.S. tariffs on pharmaceutical imports. Analysts forecast a strong price target, suggesting signifi

Key Highlights: AstraZeneca (AZN) shows substantial growth prospects with strategic acquisitions, targeting $80 billion in sales by 2030. Analysts predic

President Donald Trump has declared that his administration is on the brink of imposing a significant tariff on pharmaceuticals imported from foreign countries.

AstraZeneca (AZN) shares increased by 8% last quarter, bolstered by key EU drug approvals. Analysts forecast a potential upside of 34.49% with an averag

AstraZeneca's Imfinzi receives EU approval for NSCLC treatment with chemotherapy. Analysts predict a potential 34.49% upside for AstraZeneca stock. C

AstraZeneca and Daiichi Sankyo secure EU approval for Enhertu, expanding treatment options for breast cancer patients. Analysts forecast significant ups

AstraZeneca's SERENA-6 Phase III trial shows promising results for camizestrant in breast cancer treatment. Analysts forecast a significant potential up

Key Takeaways: AstraZeneca (AZN) is forecasted to have a potential upside of over 33% based on current analyst price targets and GF Value estimates. The

Pharma warns EU of US exodus due to tariffs, risking billions in investment, demands policy change for competitiveness.

Chinese President Xi Jinping met with a group of global business leaders in Beijing, in an effort to boost investor sentiment as rising tariffs fuel uncertainty for the economy and international trade.

President Xi Jinping’s government is set to welcome a US senator close to Donald Trump for talks in China, as the world’s largest economies try to move forward trad…

Market Analysis by covering: S&P 500, BlackRock International Growth and Income Closed Fund. Read 's Market Analysis on Investing.com